Drug intelligence / Profile preview

LS-LBP-004

Development stage: Preclinical
Lead developer: Shanghai Lishan Biopharmaceutical
Modality: Live Biotherapeutic Products → Microbiome Therapeutics
Administration: Oral

Overview

LS-LBP-004 is a preclinical-stage synbiotic live biotherapeutic product (LBP) being developed by Shanghai Lishan Biopharmaceutical for the treatment of Autism Spectrum Disorder (ASD). The therapeutic candidate is a fixed-dose combination of the prebiotic 2'-fucosyllactose (2'-FL) and the probiotic bacterium *Bifidobacterium animalis*. LS-LBP-004 is designed to target the gut-brain axis by modulating the gut microbiota, specifically by inhibiting the growth of harmful gut bacteria and reducing the production of neuro-damaging metabolites. Shanghai Lishan Biopharmaceutical plans to advance the program by filing a technical route application under China's Decree No. 818.

Other names: 2'-FL + Bifidobacterium animalis2'-fucosyllactose + Bifidobacterium animalis

Beyond the preview

Go deeper on LS-LBP-004.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LS-LBP-004.

Explore the full profile